Brief: NanoCarrier receives orphan drug designation from FDA

Nano Holdings

19/07/2017 03:48

July 19 (Reuters) - NanoCarrier Co Ltd  4571.T  
    
    * Says its micellar nanoparticles preparation NC-6300 for 
soft tissue sarcomas has been designated to orphan drug by Food 
and Drug Administration (FDA) in U.S. 
 
    Source text in Japanese: https://goo.gl/39q2jF 
    Further company coverage: 4571.T  
 
 (Beijing Headline News) 
 ((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724; 
Reuters Messaging: Tingting.liu@thomsonreuters.com@reuters.net))